Evidence map›Paper›PMID 42201678›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

PhosSight: A Unified Deep Learning Framework Boosting and Accelerating Phosphoproteome Identification to Enable Biological Discoveries.

Ben Wang, Zhiyuan Cheng, Chengying She, Hongwei Zhao, Jiahui Zhang, Lin Lv, Zhihao Yan, Hongwen Zhu, Lizhuang Liu, Yan Fu and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ben WangShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.ORCID https://orcid.org/0009-0001-3492-520X
Zhiyuan ChengUniversity of Chinese Academy of Sciences, Beijing, China.
Chengying SheShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Hongwei ZhaoDepartment of Hepatobiliary Surgery and Transplantation, Liver Cancer Institute and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Zhongshan Hospital, Fudan University, Shanghai, China.
Jiahui ZhangShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Lin LvShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Zhihao YanShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Hongwen ZhuPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Lizhuang LiuShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Yan FuUniversity of Chinese Academy of Sciences, Beijing, China.
Xinpei YiShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.ORCID https://orcid.org/0000-0001-8562-1655

Funding

Fundamental Research Funds for the Central Universities YG2025QNA41Hundred Talents Program (Category B) of the Chinese Academy of SciencesNational Key R&D Program of China 2022YFA1004801National Natural Science Foundation of China 22304111'top Talent' Program of the Shanghai Advanced Research Institute (Chinese Academy of Sciences)
6 · The paper itself

Abstract

Protein phosphorylation is a key regulator of signaling, with mass spectrometry (MS) based phosphoproteomics serving as the premier technology for its analysis. However, phosphorylation profiling is hindered by acquisition biases: Data-Dependent Acquisition (DDA) suffers from stochastic undersampling and missing values, while Data-Independent Acquisition (DIA) faces computational bottlenecks and inefficiencies from vast spectral libraries. We present PhosSight, a unified deep learning framework designed to augment identification depth and accelerate search efficiency. PhosSight features PhosDetect, a model that explicitly encodes phosphorylation-specific physicochemical features to accurately predict peptide detectability. For DDA, PhosSight leverages predicted retention time, fragment intensity, and detectability to refine site localization and rescoring, recovering marginal, low-abundance spectra. For DIA, PhosSight utilizes detectability-guided library pruning to remove non-detectable noise, accelerating search speeds without compromising sensitivity. Benchmarking on synthetic and real-world datasets confirms PhosSight's superior performance in both modes. Applying PhosSight to a large-scale Uterine Corpus Endometrial Carcinoma (UCEC) cohort improved data completeness and expanded the quantifiable phosphoproteome. This enhanced completeness enabled the discovery of novel prognosis-associated kinase targets, such as MARK2, underscoring PhosSight as a powerful tool for biological discovery in precision oncology. Trial Registration: Not applicable. This study did not prospectively assign human participants to any health-related intervention and therefore does not constitute a clinical trial requiring registration.

Indexed as

Deep LearningPhosphoproteinsProteomeProteomicsHumansMass SpectrometryPhosphorylationPhosphoproteinsProteomecancercomputer sciencedeep learningkinasemass spectrometryphosphoproteomicsphosphorylation

Identifiers

PMID42201678
PMCPMC13335961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.